Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer - Wikidata - awgldk - TriplyDB

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

http://www.wikidata.org/entity/Q28074295

about

Making Meaningful Clinical Use of Biomarkers Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma.

P2860

Q33821481-F6FD70AA-681B-428E-BFA4-B9075CC39E2B Q55058455-9E7BB8DE-5EB5-4CD7-9029-ECC2A071F7D6

P2860

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

http://www.wikidata.org/entity/Q28074295

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@ast

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@en

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@nl

type

label

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@ast

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@en

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@nl

prefLabel

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@ast

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@en

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@nl

P1433

Q28074295-46090FCE-EFAD-4E02-8D5B-ED2CD1D0EE82

P1476

Q28074295-24A4929C-6EA4-4F8B-B0F5-ADDDF39F5D5C

P2093

Q28074295-3039D2AE-2CC2-4AB3-BF6F-949858B66803

Q28074295-94A5DADA-62C4-4372-A61F-BB60B4F255B1

P275

Q28074295-0BFA32F3-B79F-4E3B-883D-DC788D502FFE

P2860

Q28074295-01D685E5-C6B6-4569-A7E9-56694E806B62

Q28074295-04DC9BA3-D897-45E3-8053-BA5442786BEF

Q28074295-0C3B490F-CC40-46F5-9010-BA58A376F164

Q28074295-0E7D682C-9B13-49AA-9195-E74612406324

Q28074295-1650CF3D-35D0-4695-874E-5F34E5F08644

Q28074295-194933F8-07B2-4476-B99E-D990050ABA92

Q28074295-1A76DC57-EE0E-4EDC-9AE5-D3E542AF4127

Q28074295-1B24FE8C-4342-4A6D-811B-36E9AA135435

Q28074295-232D225C-1935-4625-85EF-2DF68DB391CE

Q28074295-2BD37B25-3B92-4FF7-94D4-37C2D53D720F

P2888

Q28074295-5C7B9271-F79F-43CD-9703-8F6931AC629D

P304

Q28074295-4D55E6C0-9358-4D29-B995-6838F5DEE58D

P31

Q28074295-7D2731FC-CBE9-4A73-B789-430372BBC55F

Q28074295-CE82F0A5-B93A-4D09-957B-31A315DC3A53

P3181

Q28074295-475ED654-22CF-4DDF-96AE-DC92D7567D5D

P356

Q28074295-27D6BE84-BAEE-4FFA-8E18-61244E5B00EC

P407

Q28074295-9C148D55-337D-496B-A8F4-CB788864FF33

P433

Q28074295-5F95B657-49A0-4B41-A01C-1A3F73556D08

P478

Q28074295-8CA512F3-B677-4869-875D-D7FCD1EA6662

P5008

Q28074295-17180027-8253-44A6-9104-788088D495B9

P577

Q28074295-D4ED00AB-8866-41E5-9887-EB4182EC7891

P6179

Q28074295-DE0BD2AF-6231-481B-B4C3-01043CF1E840

P698

Q28074295-A4609192-2EFF-45A0-A476-EA637E259D3E

P921

Q28074295-01BA2463-8BA4-43DC-9701-18924F4BA820

Q28074295-3E7DB18A-5554-40C8-AC80-7EA91552B19C

Q28074295-EF2DE049-EA74-4B73-A657-0E114A54BF31

P932

Q28074295-250BDC51-CA1D-4A35-9307-5190768113C7

P3181

P356

S12885-016-2886-9

P1433

P1476

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

@en

P2093

Amin S

http://www.w3.org/2001/XMLSchema#string

Bathe OF

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Circulating mutant DNA to assess tumor dynamics

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Analysis of circulating tumor DNA to monitor metastatic breast cancer

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

P2888

s12885-016-2886-9

P304

850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2662218

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S12885-016-2886-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004791388

http://www.w3.org/2001/XMLSchema#string

P698

27814715

http://www.w3.org/2001/XMLSchema#string

P921

tumor biomarkers

P932

5097425

http://www.w3.org/2001/XMLSchema#string